Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Growth Hormone in MPS I, II, and VI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A parent or legally authorized representative must provide written informed consent and comply with study assessments for the full duration of the study.~* Chronologic age ≥ 5 years and bone age ≤12 years~* Diagnosis of MPS I, II, or VI~* Height ≤ -2 SDS for age and gender~* Ability to travel to study center for evaluations.~* Ability of the participant to cooperate with study procedures, to notify a guardian of symptoms, and provide assent for participation in the study.~Exclusion Criteria:~* History of treatment with hGH~* Untreated pituitary deficiency~* Pregnancy (positive urine pregnancy test) prior to enrollment in the study~* Participation in another simultaneous medical intervention trial~* Patients with closed epiphysis~* Active neoplasm~* Orthopedic procedure of the femur within the last 6 months.~* Known or suspected allergy to trial product or related products.~* Structural lesion on brain MRI resulting in brain compression~* Any other social or medical condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.~* Obstructive sleep apnea without BiPAP or tonsillectomy/adenoidectomy treatment.~* CNS shunt.~* Abnormal cardiac function based on echocardiogram within 6 months prior to enrollment :~* Ejection fraction less than 50%~* Left ventricular chamber size greater than or less than 2 standard deviations of normal for body surface area~* Left ventricular wall thickness greater than or less than 2 standard deviations of normal for body surface area~* More than mild to moderate aortic insufficiency with abdominal aortic run-off~* More than mild to moderate mitral insufficiency with pulmonary hypertension~* Abnormal pulmonary function based on pulmonary function tests within 6 months prior to enrollment:~* abnormal FVC \< 80% of predicted for age, gender, and height~* abnormal FEV1 \< 80% predicted for age, gender, and height~* abnormal FEV1/FVC~* abnormal oxygen saturation

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Growth hormone treatmen (Type: EXPERIMENTAL): Growth hormone treatment arm. Somatropin (DNA origin)
- No growth hormone treatment in year 1 (Type: NO_INTERVENTION): No growth hormone treatment in year 1; option for treatment in year 2 open-label period.

Based on this trial design, predict the completion outcome and termination type (if applicable).